Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $282.0 million.

  • Beam Therapeutics' Cash & Equivalents rose 16.40% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year increase of 16.40%. This contributed to the annual value of $282.0 million for FY2024, which is 35.31% down from last year.
  • Beam Therapeutics' Cash & Equivalents amounted to $282.0 million in FY2024, which was down 35.31% from $435.9 million recorded in FY2023.
  • Beam Therapeutics' 5-year Cash & Equivalents high stood at $560.0 million for FY2021, and its period low was $162.2 million during FY2020.
  • Over the past 3 years, Beam Therapeutics' median Cash & Equivalents value was $282.0 million (recorded in 2024), while the average stood at $316.9 million.
  • In the last 5 years, Beam Therapeutics' Cash & Equivalents soared by 335.70% in 2020 and then plummeted by 58.43% in 2022.
  • Yearly analysis of 5 years shows Beam Therapeutics' Cash & Equivalents stood at $162.2 million in 2020, then skyrocketed by 245.31% to $560.0 million in 2021, then crashed by 58.43% to $232.8 million in 2022, then skyrocketed by 87.27% to $435.9 million in 2023, then plummeted by 35.31% to $282.0 million in 2024.